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Abstract: The need to track and evaluate the fate of transplanted cells is an important issue in 
regenerative medicine. In order to accomplish this, pre-labelling cells with magnetic resonance 
imaging (MRI) contrast agents is a well-established method. Uptake of MRI contrast agents 
by non-phagocytic stem cells, and factors such as cell homeostasis or the adverse effects of 
contrast agents on cell biology have been extensively studied, but in the context of nanopar-
ticle (NP)-specific parameters. Here, we have studied three different types of NPs (Endorem®, 
magnetoliposomes [MLs], and citrate coated C-200) to label relatively larger, mesenchymal 
stem cells (MSCs) and, much smaller yet faster proliferating, multipotent adult progenitor cells 
(MAPCs). Both cell types are similar, as they are isolated from bone marrow and have substantial 
regenerative potential, which make them interesting candidates for comparative experiments. 
Using NPs with different surface coatings and sizes, we found that differences in the prolifera-
tive and morphological characteristics of the cells used in the study are mainly responsible for 
the fate of endocytosed iron, intracellular iron concentration, and cytotoxic responses. The 
quantitative analysis, using high-resolution electron microscopy images, demonstrated a strong 
relationship between cell volume/surface, uptake, and cytotoxicity. Interestingly, uptake and 
toxicity trends are reversed if intracellular concentrations, and not amounts, are considered. 
This indicates that more attention should be paid to cellular parameters such as cell size and 
proliferation rate in comparative cell-labeling studies.
Keywords: cell labeling, MR contrast agents, transmission electron microscopy, mesenchymal 
stem cells, multipotent adult progenitor cells, magnetic resonance imaging, nanoparticles, iron 
oxide
Introduction
Mesenchymal stem cells (MSCs) and multipotent adult progenitor cells (MAPCs), 
both isolated from bone marrow, are two stem cell types that are currently under 
extensive investigation.1–5 Due to their origin, bone marrow-derived stem cells are 
less debated from an ethical point of view than embryonic stem cells (ESCs). MSCs 
can differentiate into a number of mesenchymal phenotypes, including adipocytes, 
osteocytes, chondrocytes, and myocytes.6–8 MSCs can also inhibit the function of 
T-cells, B-cells, and dendritic cells, and are therefore being tested clinically in 
immune disorders such as graft versus host disease (GVHD) and Crohn’s disease.9,10 
MAPCs were first isolated by Jiang et al11 in 2002 and have the ability to differenti-
ate into smooth muscle cells, osteocytes, functional hepatocyte-like cells, and into 
a neuroectodermal lineage.12 Recent work has indicated that rat extra-embryonic 
endodermal precursor cells (rXENP), rat hypoblast stem cells (rHypoSCs), and rat 
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MAPCs (rMAPCs) have highly similar gene expression 
profiles and developmental potential.13 Thus, the HypoSC/
XENP/MAPC phenotype provides a cell model for studying 
stem cell plasticity, reprogramming, transplantation toler-
ance, and others, which is crucial for mechanistic studies 
in regenerative medicine.13,14
When considering therapeutic applications of these cells 
in humans, it is necessary to determine the fate and biodistri-
bution of the stem cells in vivo, without the need for invasive 
validation by post mortem histology. Thus, the development 
of sensitive, non-invasive imaging techniques should provide 
knowledge about the poorly understood mechanisms of the 
location, migration, and fate of stem cells post-implantation 
at different time points.15,16 Magnetic resonance imaging 
(MRI) is one of the most attractive non-invasive imaging 
modalities due to its very high resolution and soft tissue 
contrast, which are requirements for stem cell tracking in 
different disease models.15,17–20 However, the sensitivity of 
MRI is limited when compared with other imaging modali-
ties such as X-ray computed tomography (CT), positron 
emission tomography (PET) and optical imaging.21–23 In 
order to detect cells by MRI, it is necessary to pre-label them 
with MR-visible contrast agents. The majority of studies 
have used iron oxide-based nanoparticles (NPs) due to their 
relatively high sensitivity and their acceptable biocompati-
bility.15,17,18,24,25,26
Several studies have evaluated potential toxic or adverse 
effects of intracellular iron oxide in cells, where the major 
focus has been the comparison of different NP-related prop-
erties (size, coating, and concentrations).25,27 Furthermore, 
in studies where material-related properties have been the 
subject of scrutiny, cell-related properties have rarely been 
addressed. Here, we chose two similar but morphologically 
distinct stem cell types (MSCs and MAPCs) because of 
differences in their proliferative capacities (MSCs being 
a model for slow proliferation, and MAPCs being a model 
for highly proliferative cells) and average cell sizes (MSCs: 
30–50 µm and MAPCs 9–14 µm diameter). Using these 
cells, we studied the fate of three different types of particles 
with different sizes and surface charges, namely Endorem® 
(Guerbet, Roissy, France) (dextran-coated), magnetolipo-
somes (MLs, phospholipid-coated), and C-200 (citrate 
coated), to validate uptake efficiency, their intracellular 
distribution, and potential toxicity. Using ultrastructural 
analysis, we focused on evaluating the intracellular iron 
content and the fate of NPs after endocytosis. Thereby, 
we also assessed the relationship between available cell 
volume/surface area and possible adverse reactions by 
the cells.
Materials and methods
cell lines
All experiments were performed using MAPCs and MSCs. 
Isolation of MAPCs and MSCs has been described else-
where.11,28–30 Both cell types were acquired from the Stem 
Cell Institute Leuven (Katholieke Universiteit, Leuven, 
Belgium). MAPCs were grown in 60% low-glucose 
Dulbecco’s  Modified Eagle’s Medium (Gibco®, Ghent, 
Belgium), 40% MCDB-201, insulin–transferrin–selenium 
(formulation contains 1.0 mg/mL recombinant human insu-
lin, 0.55 mg/mL human transferrin, and 0.5 µg/mL sodium 
selenite), linoleic acid bovine serum albumin (100 mg/mL 
bovine serum albumin), 10−9 M dexamethasone, 10−4 M 
ascorbic acid 3-phosphate, 10 ng/mL mouse epidermal 
growth factor (all components were from Sigma, Bornem, 
Belgium). Penicillin (100 units) and 100 µg of streptomy-
cin (Cellgro, Manassas, VA, USA), 2% fetal bovine serum 
(HyClone, Aalst, Belgium), 10 ng/mL human platelet-
derived growth factor (R&D Systems, Minneapolis, MN, 
USA), 1,000 units/mL mouse leukemia inhibitory factor 
(Chemicon, Billerica, MA, USA) were added to avoid dif-
ferentiation. In addition, 0.7% β-mercaptoethanol (Gibco) 
was added fresh. The medium was sterilized using a 0.22 µm 
filter (Millipore, Overijse, Belgium) and kept at 4ºC for up 
to 2 weeks at a pH of 7.2. Cells were split every 36–48 hours 
at 80% confluence. MSCs were maintained in medium 
containing Iscove’s Modified Dulbecco’s Medium (Gibco) 
supplemented with 10% fetal bovine serum (HyClone), 10% 
horse serum (Biochrom, Berlin, Germany), 1% L-glutamine 
(Gibco), and 100 units of penicillin and 100 µg of strep-
tomycin (Cellgro). Cells were split every 60–72 hours at 
70%–80% confluence.
Nanoparticles
Labeling experiments were performed using 1) the small 
superparamagnetic, iron oxide-based NPs Endorem® 
(Guerbet, Roissy, France), 2) the very small iron oxide parti-
cles (VSOPs) C-200 (Ferropharm GmbH, Teltow, Germany), 
and 3) in-house synthesized superparamagnetic cationic 
MLs as described in De Cuyper and Joniau.31 In short, cat-
ionic MLs were made starting with lauric acid-coated Fe
3
O
4
 
NPs (14.1±0.4 nm) in a two-step process as described in 
De Cuyper and Joniau31 and Soenen et al.32 High-gradient 
magnetophoresis was employed to purify the magnetic 
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particles, which were coated with a lipid bi-layer consisting 
of a neutral dimyristoylphosphatidylcholine (Avanti Polar 
Lipids, Alabaster, AL, USA) matrix (96.7%) and further 
bestowed with 3.3% cationic distearoyl-trimethylammonium 
propane (Avanti Polar Lipids). A detailed description of the 
particles and their labeling concentrations can be found in 
Table 1. Poly-L-lysine (PLL, 388 kDa, Sigma) was used as 
transfection agent whenever it was necessary to improve the 
cellular uptake of NPs as described previously.33
cell labeling
From initial optimization experiments (this study and 
Crabbe et al33), we used Endorem® with and without PLL with 
a labeling concentration of 0–400 µg Fe/mL medium. Different 
iron concentrations were used for labeling MAPCs and MSCs 
with VSOPs and MLs as indicated in Table 1. For all labeling 
experiments, the initial seeding density for both cell types was 
adapted from previously published studies where MAPCs were 
seeded at 5 × 102 cells/cm2 and MSCs at a higher cell density of 
40 × 102 cells/cm2.28,30 The number of cells used for the various 
experiments is mentioned under the respective sections. Co-
incubation with NPs was optimized according to Crabbe et al 
for 4–48 hours and finally performed for 24 hours.33
cellular iron content
Cells were seeded at an initial seeding density (MAPCs: 
5 × 102 cells/cm2, MSCs: 40 × 102 cells/cm2) and labeled with 
different labeling concentrations for 24 hours. After co-incu-
bation, cells were washed three times with phosphate buffered 
saline (PBS) and incubated in iron-free medium for 4 hours. 
Afterwards, cells were trypsinized and counted. Pellets of 
105 cells were lysed with concentrated 3.7% HCl (Vel labs, 
Leuven, Belgium). Samples were further homogenized 
with distilled water. For quality control purposes, standard 
solutions of 0.1, 0.5, and 1.0 ppm were measured before the 
first sample and after every tenth sample. Quantification of 
the iron content in the cells was performed with inductively 
coupled plasma optical emission spectrometry (ICP-OES, 
Varian, 720ES, Santa Clara, CA, USA).
cell proliferation and metabolic activity
To evaluate the effect of labeling on the proliferative capac-
ity and viability of the cells, a population doubling time and 
a 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay was performed. Population doubling 
times were assessed by total cell count using an automatic 
cell counter (Chemometec, Lillerod, Denmark). Population 
doubling times were determined using t × ln (2)/ln (A/A0), 
where t is the time between two cell counts, A is the number 
of cells at the end of the incubation, and A0 is the initial num-
ber of cells. The population doubling time of the labeled cell 
population was followed for 6 days for MAPCs and 9 days 
for MSCs post-labeling.
Cell viability was assessed post-labeling by the MTT assay 
as originally described by Mosmann.34 MAPCs and MSCs 
were plated at the initial seeding density and incubated with 
different NPs using the above-mentioned conditions. After 
labeling, all samples were washed three times with PBS 
(without Mg2+ and Ca2+) and further incubated for 4 hours 
in iron-free medium. Cells were detached using 0.05% 
trypsin-ethylenediaminetetraacetic acid (EDTA; Gibco) and 
transferred into a 96-well plate at 1–2 × 104 cells/well for 
MAPCs and 5–10 × 104 cells/well for MSCs. These cells were 
allowed to adhere and were incubated with the MTT solution 
(0.5 mg/mL in medium; Sigma-Aldrich, Bornem, Belgium) 
for 2 (MAPCs) and 4 (MSCs) hours at 37°C and 5% CO
2
. The 
medium was then removed and 100 µL lysis buffer (1% Triton 
X-100 in isopropanol) was added to each well and extensively 
mixed. The optical density was then measured at 570 nm using 
an absorbance plate reader (Wallac, Victor2, Perkin Elmer, 
Zaventem, Belgium). The viability of cells was represented 
as % viability normalized to non-labeled samples (100%).
Confirmation of NP uptake using  
transmission electron microscopy   
(TeM) and Prussian blue staining
To confirm uptake of NPs and their intracellular distribution, 
TEM was performed. For TEM analysis, cells were plated at 
Table 1 Nanoparticles used for different cell labeling conditions
Particles Types of 
particles
Hydrodynamic  
size of particles
Coating  
material
MAPCs labeling concentration  
(μg Fe/mL in medium)
MSCs labeling concentration 
(μg Fe/mL in medium)
endorem® sPIOs 80–120 nm Dextran 50–400 50–400
Mls UsPIOs 40 nm lipid 20–50 50–400
c-200 VsOPs 8–10 nm citrate 50–200 50–200
Abbreviations: Mls, magnetoliposomes; Mscs, mesenchymal stem cells; sPIOs, superparamagnetic iron oxides; UsPIOs, ultrasmall superparamagnetic iron oxides; 
VsOPs, very small iron oxide particles; MaPcs, multipotent adult progenitor cells. 
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their initial seeding density (MAPCs: 5 × 102 cells/cm2, MSCs: 
40 × 102 cells/cm2) and labeled with NPs under different label-
ing conditions for 24 hours. After labeling with NPs, cells were 
washed and incubated in iron-free medium for 4 hours. Cells 
were detached using 0.05% trypsin-EDTA (Gibco) and trans-
ferred to plastic Nunc Thermanox® (Thermo Scientific, Roch-
ester, NY, USA) coverslips at a density of 2.5–5 × 104 cells/
cm2. Immediately after adhering on the cover slip surface, cells 
were fixed with 2% glutaraldehyde (Laborimpex NV, Brus-
sels, Belgium) in 0.05 M sodium cacodylate buffer (Aurion, 
Wageningen, The Netherlands) at pH =7.3 and a temperature 
of 4°C. Samples were further prepared as described in Struys 
et al.35 Briefly, following embedding in epoxy resin (araldite; 
Aurion, Wageningen, The Netherlands), samples were cut 
in sections of 40–60 nm, using a Leica EM UC6 micro-
tome (Leica, Groot Bijgaarden, Belgium). They were then 
transferred to 50 mesh copper grids (Aurion, Wageningen, 
The Netherlands) coated with 0.7% formvar. Samples were 
automatically stained with 0.5% uranyl acetate and stabilized 
in a solution of lead citrate (both from Laurylab, Saint-Fons, 
France) using a Leica EM AC20 (Leica).35 TEM analysis 
was performed with a Philips EM208 S electron microscope 
(Philips, Eindhoven, The Netherlands) provided with a Morada 
Soft Imaging System camera to acquire high-resolution TEM 
images. The images were processed digitally with the iTEM-
FEI software (Olympus SIS, Münster, Germany).
For Prussian blue staining, labeled cells were fixed in 
4% paraformaldehyde (Sigma) for 15 minutes at room 
temperature. Solutions of 2% HCl (Vel Labs, Leuven, 
Belgium) and 2% potassium ferrocyanide (Sigma) were 
mixed just before incubation with cells for 15 minutes. Eosin 
(Sigma) was used for counter staining.
Quantification of NPs per cell volume
The relationship between available cell volume and the 
intracellular iron concentrations was determined based on 
the TEM (volume) and ICP-OES (iron content) data. Those 
data were then set in relation to the cell viability experiments. 
For quantification purposes, we assume that the distribution 
of particles in the endosomes is homogenous, and that cells 
and NPs are spherical in shape. The dimensions of the cells 
and nuclei (n=25) were determined experimentally from TEM 
data. The cell cytoplasm volume was calculated by substract-
ing the volume of the nucleus from total cell volume.
Magnetic resonance imaging
Labeled cells were scanned by MRI in order to assess the 
detectability threshold for different amounts of cells and 
for different NP concentrations. To prepare MR phantoms 
for imaging, labeled cells were washed with PBS. After 
trypsinizing and centrifugation (1,500 rpm), cell suspen-
sions were made using the respective cell culture medium. 
After cell counting, 105 cells were again pelleted and 
resuspended in 100 µL of PBS. These cell suspensions 
(1,000 cells/µL) were mixed with 1.5% agarose (Sigma) in a 
1:1 ratio and transferred into 250 µL microcentrifuge tubes 
one-third prefilled with solidified agarose. All microcentri-
fuge tubes (now containing 500 cells/µL) were assembled in 
a pre-made matrix made of 1.5% agarose.35 Upon solidify-
ing, the agarose gel phantoms were scanned using a 9.4 T 
Bruker Biospec small animal MR scanner (Bruker Biospin, 
Ettlingen, Germany; horizontal bore 20 cm) equipped with 
actively shielded gradients (600 mT m−1). A quadrature 
radio-frequency resonator (transmit/receive; inner diam-
eter 7 cm, Bruker Biospin) was used for data acquisition. 
Two-dimensional multi-slice-multi-echo (MSME) scans 
were acquired for the calculation of T2 values (TR [repeti-
tion time] =3,000 ms and 16 TE [echo time] increments of 
8 ms, 256 × 256 matrix with 234 × 234 µm in plane reso-
lution). Three-dimensional, high-resolution T2*-weighted 
MR images were acquired using a gradient echo sequence 
(FLASH, TR =200 ms, TE =15 ms). The field of view was 
6.0 × 6.0 × 2.25 cm, resulting in an isotropic resolution of 
234 µm3. Images were processed with Paravision 5.0/5.1 
(Bruker Biospin, Ettlingen, Germany).
label dilution
To validate cell detection after further proliferation, the 
dilution of the NPs was followed for MAPCs and MSCs for 
1 week post-labeling using ICP-OES, three-dimensional 
T2* weighted high-resolution MR images and TEM (using 
above-mentioned protocols). Hereby, cells were split regu-
larly and always seeded at their initial seeding density in 
NP-free medium.
statistical analysis
Statistical analysis was performed using Graphpad Prism 
5 software (Graphpad, La Jolla, CA, USA). Significant 
differences between experimental groups were determined 
using the two-way analysis of variance test with a Tukey 
post or Bonferroni post-test after normalizing the data. Plot-
ted data were represented as mean ± standard error (SE). 
Whereas iron concentration values (in fg/µm3) are indicated 
as mean ± standard deviation (SD) throughout the text. 
P-values # 0.05 were considered statistically significant at 
the 5% significance level.
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Results
Cellular iron quantification
Iron uptake was quantified using ICP-OES. Figure 1A and B 
show uptake of various NPs by MSCs and MAPCs for all 
concentrations of NPs. Conjugation of PLL to Endorem® 
was performed in order to evaluate whether intracellular iron 
concentrations can be further elevated at lower concentra-
tions in the culture medium. Addition of PLL to Endorem® 
increased the intracellular iron content by four-fold in 
MAPCs, whereas MSCs showed a six-fold increase at lower 
incubation concentrations of 50 µg Fe/mL. Very low amounts 
of iron were found in MSCs compared with MAPCs when 
labeled with 50µg Fe/mL of medium using cationic MLs and 
VSOPs. Increase of iron in the medium for labeling with 
cationic MLs and VSOPs resulted in increased uptake until 
toxic effects were seen. This was not the case for labeling 
with Endorem® ± PLL. Uptake saturation was seen when 
MAPCs were labeled with Endorem® + PLL (for 50–400 µg 
Fe/mL), corresponding to intracellular amounts of iron up 
to 18 pg/cell. Utilization of TEM-based cell volumes (see 
also Table 2) indicated that MAPCs have a ten times smaller 
volume than MSCs, which explains the much lower iron con-
centration (fg/µm3) in MSCs for a similar absolute amount 
of intracellular iron when compared with MAPCs. Due to 
this large difference in cell volumes between MSCs and 
MAPCs, the uptake of iron was also expressed in intracel-
lular concentrations (Figure 1). While the total iron content 
per cell was, to a large extent, comparable between the two 
30
End
20
10
0
50
****
****
****
200
Iron concentration in medium (µg Fe/mL)
MSCsA
In
tr
ac
el
lu
la
r 
ir
o
n
 p
er
 c
el
l (
in
 p
g
/c
el
l)
***
***
**
****
400
**
End + PLL
VSOPs MLs
30 End
20
10
0
50
***
200
Iron concentration in medium (µg Fe/mL)
MAPCsB
In
tr
ac
el
lu
la
r 
ir
o
n
 p
er
 c
el
l (
in
 p
g
/c
el
l)
*
400
End + PLL
VSOPs MLs
1.5
End
1.0
0.5
0.0
50
****
****
****
200
Iron concentration in medium (µg Fe/mL)
C
In
tr
ac
el
lu
la
r 
ir
o
n
 c
o
n
ce
n
tr
at
io
n
 (
fg
/µ
m
3 )
***
***
**
****
400
**
End + PLL VSOPs MLs
20 End
10
15
5
0
50
***
200
Iron concentration in medium (µg Fe/mL)
D
In
tr
ac
el
lu
la
r 
ir
o
n
 c
o
n
ce
n
tr
at
io
n
 (
fg
/µ
m
3 )
*
400
End + PLL
VSOPs MLs
#
#
#
#
#
#
#
#
Figure 1 Quantification of iron uptake and intracellular concentration: (A and B) iron uptake in both types of cells was quantified using ICP-OES for all labeling concentrations 
(A) Mscs, (B) MaPcs. (C and D) Intracellular iron concentration (iron mass/volume of cytosol) was plotted against labeling conditions for (C) Mscs and (D) MaPcs, 
indicating that a higher iron concentration was present in MaPcs.
Notes: *P,0.05; **P,0.01; ***P,0.001; ****P,0.0001. #Toxic concentration.
Abbreviations: end, endorem®; IcP-Oes, inductively coupled plasma optical emission spectrometry; MaPcs, multipotent adult progenitor cells; Mls, magnetoliposomes; 
Mscs, mesenchymal stem cells; Pll, poly-l-lysine; VsOPs, very small iron oxide particles.
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Table 2 calculation of intracellular iron concentration per cell volume
Labeling condition  
(μg Fe/mL)
Size of  
particles (nm)
Iron uptake  
(pg/cell)*
Volume of  
particles (μm3)
Volume of  
cytoplasm (μm3)†
% volume  
occupied
Iron concentration 
(fg/μm3)
MaPcs
 Mls (50) 40 10.4±0.9 2.12±0.9 1,400 0.156 7.4
 VsOP (50) 10 18.4±3.9 3.76±3.9 1,400 0.276 13.1
Mscs
 Mls (50) 40 1.3±0.2 0.27±0.2 18,000 0.001 0.1
 Mls (400) 40 14±1.0 2.86±1.0 18,000 0.016 0.8
 VsOPs (50) 10 2.8±0.4 0.41±0.4 18,000 0.002 0.2
 VsOPs (200) 10 11.7±0.8 2.39±0.8 18,000 0.013 0.7
Notes: *Mean ± se; †volume of cytoplasm =(volume of the cell) – (volume of nucleus). cytoplasm volume calculations are based on TeM.
Abbreviations: MaPcs, multipotent adult progenitor cells; Mls, magnetoliposomes; Mscs, mesenchymal stem cells; se, standard error; TeM, transmission electron 
microscopy; VsOPs, very small iron oxide particles.
stem cell lines, an up to ten-fold higher iron concentration 
(fg/µm3) was observed in MAPCs when compared with 
MSCs (Figure 1C and D).
effects on cell proliferation  
and metabolic activity
The effect of labeling on cell viability and proliferation was 
assessed by comparing total cell counts and the MTT assay 
post-labeling. Proliferation was determined using population 
doubling time (PDT) from total cell counts for both cell types.
MAPCs and MSCs were labeled with NPs at different 
concentrations as shown in Table 1. The effect on cell survival 
was determined 24 hours after adding the respective NPs 
and is shown in Figure 2 and Figure S1. A significant effect 
on cell survival was observed in MAPCs after labeling with 
VSOPs at 50 µg Fe/mL medium (corresponding to 13.1±4.7 
fg/µm3) or higher and after labeling with MLs at a concentra-
tion above 20 µg Fe/mL medium (corresponding to 2.8±2 fg/
µm3 at 20 µg Fe/mL medium and 7.4±0.9 fg/µm3 at 50 µg 
Fe/mL medium, respectively). Statistically non-significant, 
minor reductions of MAPC survival after labeling with high 
concentrations of Endorem® (± PLL) were detected. Similar 
trends were seen for MSC survival compared to MAPCs but 
only starting at higher iron concentrations in the medium 
(Figure 2B).
For labeling MAPCs with Endorem®, we only noticed a 
marginal but non-significant increase in the doubling time of 
cells labeled with the highest concentrations when compared 
with unlabeled cells (Figure 2C). Similarly, statistically 
insignificant effects on MSC proliferation were found fol-
lowing exposure to different Endorem® (± PLL) concentra-
tions (Figure 2D). For all further experiments, we focused 
on non-toxic NP concentrations.
MTT assays were performed after cell labeling with 
all NP concentration conditions as shown in Table 1. 
Figure 2E indicates significant reductions in metabolic 
rates for MAPCs when labeled with 200 µg Fe/mL medium 
or higher amounts of Endorem® + PLL (corresponding to 
12.8±0.5 fg/µm3) and VSOPs and MLs ($50 µg Fe/mL 
medium, corresponding to 13.1±4.7 and 7.4±0.9 fg/µm3, 
respectively) compared with non-labeled controls. However, 
when the labeling concentrations of NPs in the medium were 
the same, the metabolic activity of MSCs was unaltered. No 
effect on the metabolic activity was seen for both cell types for 
concentrations in the medium that were lower than mentioned 
in Figure 2E. After comparing metabolic data (Figure 2E) and 
cell survival data (Figure 2F) post-labeling, it was observed 
that MSCs were generally more tolerant to higher iron con-
centrations in the medium than were MAPCs.
Although MAPCs seemed to be more susceptible to high 
iron concentrations in the medium than MSCs, their intracel-
lular iron concentration was, in many cases, much higher than 
for the much larger MSCs (see Table 2). When adjusted for 
the intracellular volume, similar or even higher iron concen-
trations were found to be toxic for MAPCs compared with 
MSCs (see Table 2, Figures 1, 2E and F, and Figure S1).
NPs internalization
To assess the ultrastructural properties of cells post-labeling 
with NPs, and to distinguish between intracellular iron and 
potentially extracellular membrane-bound iron, labeled cells 
were studied with TEM (Figures 3 and 4). Figure 3A clearly 
indicates that particle uptake occurred via endocytosis. The 
presence of cellular extensions, pseudopodia, was detected 
surrounding NPs that accumulated along the cell membrane 
prior to uptake. This also emphasizes the need to incubate 
cells in iron-free medium before engraftment in vivo so that 
remaining extracellular iron can be internalized and so label 
transfer to host cells can be avoided. For MAPCs, labeling 
with Endorem® resulted in intracellular particle clustering, 
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Figure 2 cell proliferation and viability post-labeling: (A) MaPcs, when labeled with endorem® (± Pll), VsOPs, and Mls with different labeling concentrations and counted, 
showed a significant reduction in the cell count at 50 µg Fe/ml medium of VsOPs and Mls, whereas a marginal decrease in the cell count was observed for 50 µg Fe/ml 
of endorem® + Pll. (B) MSCs, when labeled with all NPs, showed significant reductions in the total cell count only at 200 µg Fe/ml of VsOPs and 400 µg Fe/ml of Mls. 
(C and D) No significant differences were observed with respect to population doubling time (PDT) when MAPCs and MSCs were labeled with Endorem® and followed for 
6 and 9 days, respectively. (E) cell viability (MTT) and (F) cell survival post-labeling was plotted for different labeling conditions.
Notes: *P<0.05; **P,0.01; ***P,0.001; ****P,0.0001.
Abbreviations: end, endorem®; MaPcs, multipotent adult progenitor cells; Mls, magnetoliposomes; Mscs, mesenchymal stem cells; MTT, 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide; NPs, nanoparticles; Pll, poly-l-lysine; VsOPs, very small iron oxide particles.
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thereby forming multiple ‘rod-like’ structures for all labeling 
concentrations (50–400 µg Fe/mL medium, corresponding 
to 3.2±0.2 to 16.7±2.7 fg/µm3, Figure 3B and C). In con-
trast, homogenous distribution of Endorem® particles in 
endosomes was observed when PLL (1.5 µg/mL) was added 
during incubation with low concentrations of Endorem® (at 
50 µg Fe/mL medium, corresponding to 12.8±1.1 fg/µm3, 
Figure 3D). With increased NP concentrations in the medium, 
‘rod like’ structures also reappeared in the presence of PLL 
(Figure 3E). Similar observations were made for MSCs when 
labeled with Endorem® (Figure 3F–K). For comparison with 
electron microscopy images of pure particles, we refer the 
reader to Hodenius et al36 for citrate-coated particles, Jung 
and Jacobs37 for Endorem®, and to Figure S2 for the MLs.
When MAPCs were incubated with VSOPs, they showed 
high endocytotic uptake with labeling concentrations of 
50 µg Fe/mL medium (corresponding to 13.1±4.7 fg/µm3). 
MAPCs with higher incubation concentrations of 
200 µg Fe/mL also showed a dilated endoplasmic reticu-
lum and the presence of vacuoles, which suggests cel-
lular stress (Figure 4A and B), further supporting the 
results from the MTT assays and reduced cell counts 
(Figure 2A and E). MSCs showed a steady increase in the 
uptake of VSOPs (confirmed with ICP-OES, Figure 1), 
with increased concentrations in the medium up to 200 
µg Fe/mL. Similar to MAPCs, indications of stress were 
also seen for MSCs at concentrations of at least 200 µg 
Fe/mL medium (corresponding to 0.7±0.7 fg/µm3, Fig-
ure 4D). As labeling with MLs resulted in a reduction of 
metabolic activity of MAPCs at concentrations as low 
as 50 µg Fe/mL, we did not further analyze the ultra-
structure of MAPCs labeled with MLs. TEM of MSCs 
showed homogenously distributed NPs in endosomes and 
showed no indication of stress when labeled with MLs 
MAPCs
MSCs
A B C
D E
F G H
I J K
Figure 3 Ultra-structural analysis of MaPcs and Mscs with TeM. (A) Endocytosis was confirmed by the presence of pseudopodia (arrow) and NPs in endosomes. (B and C) 
MaPcs labeled with endorem® showed ‘rod-like’ structures in the endosomes at lower (50 µg Fe/ml) and at higher (400 µg Fe/ml) iron concentrations in the medium 
(see arrow in panel B and C). (D) addition of Pll avoided ‘rod-like’ structures at lower iron concentrations (50 µg Fe/ml medium), but (E) indicates presence of ‘rod-like’ 
(arrow) structures at higher concentrations (400 µg Fe/ml medium). (F) Non-labeled Mscs. (G) Mscs labeled with endorem® using 50 µg Fe/ml medium indicated the 
presence of rod-like structures, which is further highlighted in (H), the same image as (G) but with a higher magnification. (I) homogenously distributed NPs were observed 
in endosomes when Pll was added to endorem® (50 µg Fe/ml medium). (J and K) rod-like structures were still present in Mscs for higher concentrations of 200 µg Fe/ml 
and 400 µg Fe/ml in the medium, respectively.
Notes: scale bar: A, C–E, H–K =2 µm; B =500 nm; F–G =5 µm.
Abbreviations: e, endosomes; l, lysosomes; MaPcs, multipotent adult progenitor cells; Mscs, mesenchymal stem cells; N, nucleus; NPs, nanoparticles; Pll, poly-l-lysine; 
TeM, transmission electron microscopy.
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up to 400 µg Fe/mL medium (corresponding to 0.8±0.1 
fg/µm3, Figure 4E).
Label internalization was also confirmed by Prussian 
blue staining. Figure 4G shows Prussian blue staining of 
MSCs labeled with different NPs. Maximum staining was 
observed when MSCs were labeled with Endorem® + PLL 
(at 50 µg Fe/mL medium), which correlates with ICP-OES 
measurements (Figure 1).
Both cell types differed in their apparent toxicity profile 
and intracellular iron uptake when labeled with the same 
particles. Smaller cells such as MAPCs were susceptible to 
lower concentrations in the medium (50 µg Fe/mL) when 
labeled with VSOPs and MLs, but also showed significantly 
higher uptake and intracellular amounts of iron. When based 
on intracellular concentrations, MAPCs and MSCs were 
similarly tolerant to the various contrast agents, highlighting 
the importance of expressing parameters such as toxicity and 
iron uptake in concentrations rather than amounts.
MrI detectability
Cells labeled with NPs were visualized due to their effect 
on the magnetic susceptibility and thereby reduced signal 
intensity in T2*-weighted MR images. For comparative 
MRI sensitivity studies, we kept the cell density low and 
constant (500 cells/µL) for phantoms containing labeled 
MAPCs and MSCs. Figure 5 shows three-dimensional T2*-
weighted MRI scans and T2 relaxation time measurements 
post-labeling. Endorem®-labeled MAPCs showed a gradual 
Endorem® Endorem® + PLL VSOPs MLs
50 µg Fe/mL
100 µg
2 µm 2 µm
2 µm 2 µm
2 µm
2 µm
200 µg Fe/mL
A
D
G
B
E
C
F
100 µg 100 µg 100 µg
100 µg100 µg100 µg100 µg
Figure 4 Uptake confirmation of MAPCs and MSCs: (A) VsOPs (50 µg Fe/ml medium) incubated with MaPcs showed endocytotic uptake (arrow). (B) For higher iron 
concentrations of VsOPs (200 µg Fe/ml medium), MaPcs showed presence of dilated endoplasmic reticulum (arrow) and presence of big vacuoles (marked by *). (C) Mscs 
labeled with VsOPs (50 µg Fe/ml medium), showed presence of homogeneously distributed NPs in endosomes (black arrow). (D) Adverse effects were confirmed in MSCs 
labeled with VsOPs (200 µg Fe/ml medium) when vacuoles (*) and dilated ePr (arrows) were observed. (E) homogenous distribution of NPs in endosomes was clearly 
observed when Mscs labeled with Mls (arrows). (F) Non-labeled Mscs. (G) Iron uptake was also confirmed with Prussian blue staining (in MSCs with all particles).
Notes: scale bar: A–D, F =2 µm; E =10 µm; G =100 µm.
Abbreviations: ePr, endoplasmic reticulum; MaPcs, multipotent adult progenitor cells; Mscs, mesenchymal stem cells; Mls, magnetoliposomes; NPs, nanoparticles; Pll, 
poly-l-lysine; VsOPs, very small iron oxide particles.
International Journal of Nanomedicine 2013:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
4586
Ketkar-atre et al
decrease in signal intensity with increased iron concentra-
tions. Clear effects on MRI detectability due to improved 
labeling efficiency of MSCs were seen with the addition of 
PLL to Endorem®, reducing the signal intensity down to 40% 
with respect to non-labeled cells at the lowest concentration 
of 50 µg Fe/mL medium (corresponding to 1.1±0.1 fg/µm3, 
see Figure 5A). These reductions in the signal intensity cor-
relate well with ICP-OES data from Figure 1.
The only tolerable concentration for MAPC labeling 
with MLs was 20 µg Fe/mL medium (corresponding to 
2.8±2 fg/µm3), which also resulted in detectable cells in agar 
phantoms. Due to the adverse effects of MLs on MAPC sur-
vival, higher ML concentrations were excluded from further 
comparisons. Unlike MAPCs, MSCs only displayed adverse 
effects on cell biology when labeled with the highest NP con-
centration 400 µg Fe/mL medium (corresponding to 0.8±0.1 
fg/µm3). Although MAPCs initially showed high VSOP 
uptake (Figure 1), contrast changes and reductions in T2 val-
ues in the respective MR images was significantly lower than 
with 50 µg Fe/mL medium Endorem® (± PLL). Figure 5C and 
D shows the color-coded images of T2 relaxation times for 
MSCs and MAPCs labeled with respective NPs. T2 relaxation 
times decreased with increased iron concentrations for most 
of the labeling conditions, and showed similar trends as for 
relative signal intensity changes in three-dimensional T2*-
weighted MRI. The strongest effects were seen for MSCs 
labeled with Endorem® + PLL.
label dilution
The fate of NPs after continued cell proliferation was 
evaluated with MR three-dimensional T2*-weighted high-
resolution images and TEM. Figure 6 shows label dilution 
over time for MAPCs labeled with Endorem® (Figure 6A) 
and MSCs with Endorem® + PLL (Figure 6B). MAPCs in a 
suspension of 500 cells/µL were detectable (as hypointense 
spots) in MR scans for up to 4 days post-labeling, whereas 
MSCs, as slowly proliferating cells, were detectable until 
day 6 post-labeling with Endorem® + PLL.
Figure 6C indicates label dilution over time for 
200 µg Fe/mL medium Endorem® ± PLL and VSOPs as well 
as 50 µg Fe/mL medium of MLs. Endorem® and VSOPs were 
detectable in endosomes until day 5 post-labeling, whereas 
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Figure 5 Mr detection of labeled MaPcs and Mscs. (A and B) show the presence of hypo-intense spots of labeled Mscs and MaPcs, respectively, in Flash three-
dimensional T2*-weighted scans with cell density of 500 cells/µl. (C and D) Quantitative analysis of reduction in T2-relaxation times was determined using MsMe MrI 
experiments. Maximum reduction with respect to T2 relaxation times was seen when Mscs were labeled with endorem® + Pll.
Abbreviations: end, endorem®; MaPcs, multipotent adult progenitor cells; MrI, magnetic resonance imaging; Mscs, mesenchymal stem cells; MsMe, multi-slice-multi-echo; 
Pll, poly-l-lysine; VsOPs, very small iron oxide particles.
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MLs and Endorem® + PLL were observed in endosomes even 
after 8 days post-labeling.
Discussion
Cell labeling with iron oxide-based NPs has become a com-
mon strategy for subsequent in vitro and in vivo cell visualiza-
tion using microscopic and non-invasive imaging methods. 
Due to this increased number of applications in biological 
systems, assessment of the sensitivity, toxicity, and adverse 
effects of NPs on cell biology has become a topic of interest. 
An extensive number of studies have evaluated the effect of 
NP labeling on cell homeostasis; some of which have pointed 
to negative effects of particle incorporation on cell viability,38 
actin cytoskeleton structure,39 differentiation potential,40,41 
receptor expression,42,43 migratory capabilities,44,45 and reac-
tive oxygen species (ROS) generation,46 suggesting the need 
for in vitro evaluation before their in vivo application. The 
number of studies focusing on cell-related rather than NP-
related parameters is limited.
In this study, we used three different types of iron oxide-
based contrast agents (with respect to their size and coating) 
for labeling of two cell lines (MSCs and MAPCs) differing 
in cell size and doubling time in order to study the effect of 
cell-related factors on NP uptake and fate, using TEM for 
ultrastructural analysis. Though both cell types have a similar 
origin, they possess different properties. MAPCs represent 
Day 2
Day 5
Day 8
50
200
400
Control
50
200
400
Control
Endorem® Endorem® + PLL MLs VSOPs
MAPCs + Endorem® MAPCs + Endorem® + PLL
D 2 D 4 D 2 D 6 D 8
A B
C
Figure 6 label dilution in MAPCs and MSCs. Label dilution over time due to cell proliferation was confirmed using high-resolution three-dimensional T2*-weighted scans 
and TeM. (A) MaPcs labeled with endorem® with 200 µg Fe/ml medium (with cell density of 500 cells/µl) were detected by MrI until day 4. (B) Mscs labeled with 
endorem® + Pll at 50 µg Fe/ml medium (with cell density of 500 cells/µl) were detectable for 6 days post-labeling. (C) electron microscopy analysis was done for all 
MSC-labeling conditions. It was observed that, although MLs were taken up in significantly lower quantities than Endorem® + Pll, they degraded slowly by the intracellular 
environment and were present in the endosomes until day 8 post-labeling.
Notes: scale bar: all day 2 images = 5 µm; all day 5, 8 images = 2 µm. arrows indicate presence of NPs in endosomes for different labeling conditions.
Abbreviations: MaPcs, multipotent adult progenitor cells; Mls, magnetoliposomes; MrI, magnetic resonance imaging; Mscs, mesenchymal stem cells; NPs, nanoparticles; 
Pll, poly-l-lysine; TeM, transmission electron microscopy; VsOPs, very small iron oxide particles.
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a rare cell population that can differentiate to endothelium 
and endodermal lineages. Extensive research has been con-
ducted in isolating MAPCs from mice, rats, and humans 
(commercially available clinical grade stem cell product 
MultiStem®).11,47
cell volume and NP uptake and toxicity
In most studies, the cellular content of iron oxide-based NPs 
is expressed as an amount per cell. Considering the vast 
variability in cell size in stem and progenitor cells, the same 
amount of NPs would result in a similarly large variability 
of intracellular NP concentrations. For example, while the 
pheochromocytoma cell line PC12 is relatively small (diam-
eter of ,10 µm) and takes up less iron oxide-based NPs 
than the much larger neural progenitor cell line C17.2, the 
ultimate intracellular iron concentration was comparable.48 
Similarly, MSCs studied here have a ten times larger volume 
than MAPCs. When MSCs and MAPCs were labeled with 
VSOPs and MLs, significant variations were observed in 
the intracellular iron content and toxicity. When compared 
with MSCs, smaller MAPCs endocytosed smaller particles 
(VSOPs: 18.2±3.9 pg/cell and MLs: 10.40±0.9 pg/cell, at 
labeling concentrations of 50 µg Fe/mL medium) in higher 
quantities compared with Endorem® (4.6±1.2 pg/cell). The 
number of particles coming into contact with the cell mem-
brane is higher with decreasing diameters of the particles. 
This effect is more pronounced for the uptake by smaller 
cells (MAPCs: 9–14 µm) compared with larger cells (MSCs: 
30–50 µm). In addition to their volume occupancy (Table 2) 
due to the smaller diameter, other possible reasons for their 
toxicity could also be the lower stability of VSOPs.48,49
In addition to differences in uptake mechanisms, the iron 
storage capacity of cells might also be cell dependent. Based 
on the calculated relative volume occupied by NPs with 
respect to the total volume of available cytosol (Table 2), we 
hypothesize that every cell has some iron storage capacity 
per cell volume, and once exceeded, may cause toxicity due 
to iron overload.50 As our observations indicate a relation-
ship between cytosol volume, intracellular iron concentra-
tion, and toxicity, it would be beneficial for the comparison 
of different cell-labeling studies to express NP uptake in 
intracellular concentrations (iron mass/volume of cytosol) 
rather than amounts (mass per single cell). As indicated in 
Figure 1, similar amounts of iron in cells translate into many-
fold differences of intracellular concentrations and possibly 
explain adverse effects of NPs on cell biology. Compared 
with MAPCs, the larger MSCs were more tolerant to higher 
NP concentrations in the medium, which was evident from 
proliferation, viability, and TEM (absence of vacuoles and 
dilated endoplasmic reticulum). Although no cell differentia-
tion experiments were performed in this study, previous work 
on the same cell lines has indicated similar trends.33
Formation of aggregates
Based on the cell viability tests, MR contrast generation, and 
label dilution over time, optimal, non-toxic NP concentrations 
in the medium were selected to be 200 µg Fe/mL of Endorem® 
for MAPCs and 50 µg Fe/mL medium (corresponding to 
1.1±0.1 fg/µm3) Endorem® + PLL for MSCs. From iron 
quantification measurements and T2 maps, it was observed 
that labeling of MAPCs with Endorem® was more effective 
than Endorem® in the presence of a transfection agent, con-
firming previous observations.33 In contrast, conjugation of 
388 kDa PLL (1.5 µg/mL) showed a significant increase in 
iron uptake by MSCs without affecting their viability. TEM 
images indicated that upon Endorem® labeling, ‘rod-like’ 
aggregates were observed. These observations are in line 
with a detailed study on interactions between lipofectamine 
and Endorem® complexes, suggesting that such aggregates 
are formed in the presence of serum and that the degree of 
aggregation depends on the ratio of the transfection agent to 
NPs.51 This can be explained by inadequate surface covering 
of NPs with PLL moieties, leading to heterogeneity in local 
surface charges, thus increasing affinity for charged serum 
proteins to the complex surface, leading to protein corona.52 
It has also been shown in the literature that dextran-coated 
cores are easily metabolized when present in endosomes at a 
lower pH.53 The ‘rod-like’ structures have not been reported 
before, except for labeling experiments where cells were 
exposed to external magnetic fields.54 Those aggregates can 
potentially be beneficial in applications where pre-labeled 
cells are transplanted for longitudinal studies. If stable over 
time, such aggregates will not be further diluted with prolifera-
tion, hereby enabling longer detectability in vivo. Although 
we did not see any detrimental effects of these aggregates on 
population doubling population in follow-up experiments, 
further investigations related to the generation of ROS and 
differentiation potential would be needed.
label dilution over time
Longitudinal assessment of contrast by MRI is limited due 
to the label dilution by proliferating cells. In this study, we 
determined the fate of NPs for 1 week post-labeling with the 
help of MRI and high-resolution TEM. PDT for MSCs was 
approximately 25 hours and for MAPCs around 12 hours. 
Endorem® was only detectable for 4 days (approximately 
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eight divisions) in the rapidly proliferating MAPCs. Where 
MSCs were labeled with Endorem®, hypointense contrast 
in MRI (cell density of 500 cells/µL) was seen until day 6 
post-labeling (approximately five cell divisions). However, it 
was obvious from TEM images that these particles were pres-
ent in the endosomes until day 8 post-labeling. For in vivo 
applications, longer observation periods are possible due to 
the slower proliferation under in vivo conditions. The minor 
discrepancy in PDT and MRI detectability as seen between 
MAPC and MSC can also be explained by biodegradation of 
NPs and subsequent recycling of iron by the cells or potential 
exocytosis if cells are monitored over long periods.
Ultrastructural analysis of MSCs labeled with 50 µg Fe/mL 
medium Endorem® + PLL and MLs showed retention of 
particles in the endosomal compartment for 1 week post-
labeling. Intracellular iron concentrations immediately 
after MSC labeling were found to be much lower for MLs 
(0.1 fg/µm3) than for Endorem® + PLL (1.2 fg/µm3) at 
50 µg Fe/mL medium. The retention of NPs in the cells for 
more than 1 week for both NPs indicates a slower degradation 
of MLs compared with Endorem® + PLL, as also previously 
found for other cell types.48 This observation indicates that 
the fate of the intracellular particles is also decided by the 
coating of NPs and highlights the need for ultrastuctural 
analyses. Although cationic MLs can have adverse effects 
on cell physiology if present at high intracellular concentra-
tions, as for the smaller MAPCs, they have the advantage of 
providing information in longitudinal studies if concentra-
tions are carefully adjusted.48
Conclusion
Differences in nanoparticle interactions with different cell 
lines are not only influenced by the size, coating, surface 
charge, and other properties of the contrast agent but also 
depend on cellular parameters such as size or doubling times. 
This not only results in differences in nanoparticle uptake 
and contrast generation but also affects the assessment of 
potentially toxic responses. The cell size dependence of cell-
labeling strategies also stresses the importance of expressing 
the uptake of contrast agents in concentrations (iron mass/
volume of cytosol) rather than in amounts to allow meaning-
ful inter-study comparisons. Our results also confirm that it 
is necessary to validate cell–contrast agent interactions for 
each combination.
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Variability in contrast agent uptake by different but similar cell types
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Figure S1 adverse effects on MaPcs and Mscs after labeling with Mls. When MaPcs were labeled with Mls at different concentrations in the medium (20–50–100 µg Fe/ml), 
toxic effects were observed from 50 µg Fe/mL medium. On day 2 after labeling, a significant decrease in the total cell count relative to unlabeled control cells was observed, as 
shown in the left graph. labeled cells were re-seeded and counted on day 4 and day 6 after labeling with Mls. The total cell counts increased steadily over a period of 6 days, 
even for the higher concentration 100 µg Fe/ml medium. The MTT assay was performed on day 2 in 20, 50, 200, and 400 µg Fe/ml medium (right graph and Figure 2e), 
indicating a sharp decrease in the metabolic activity compared with unlabeled control cells. The intracellular iron concentration in the 20 µg Fe/ml medium was 2.8±2 fg/µm3 
and at 50 µg Fe/ml medium was 7.4±0.9 fg/µm3, respectively. In case of Mscs, the iron concentration at 50 µg Fe/ml medium was 0.1±0.2 fg/µm3 (Table 2), which is insignificant 
compared with MaPcs and caused no toxic effect on the metabolic activity and cell survival of Mscs until 400 µg Fe/ml medium (corresponding to 0.8±0.1 fg/µm3).
Notes: **P<0.01; ***P<0.001; ****P<0.0001.
Abbreviations: MaPcs, multipotent adult progenitor cells; Mls, magnetoliposomes; Mscs, mesenchymal stem cells; MTT, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide.
Figure S2 Transmission electron microscopy of magnetoliposomes used for cell 
labeling.
